{"id":390429,"date":"2019-05-07T00:00:00","date_gmt":"2019-05-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinop0001-2019-biopharma-retinal-vein-occlusion-executive-insights-us-2019\/"},"modified":"2026-03-31T10:46:57","modified_gmt":"2026-03-31T10:46:57","slug":"exinop0001-2019-biopharma-retinal-vein-occlusion-executive-insights-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinop0001-2019-biopharma-retinal-vein-occlusion-executive-insights-us-2019\/","title":{"rendered":"Retinal Vein Occlusion | Executive Insights | US | 2019"},"content":{"rendered":"<p>Retinal vein occlusion (RVO) is a major cause of blindness, and affected approximately 1.6 million patients in 2018 in the United States. Patients are segmented by the anatomic location of the occlusion, and therefore are classified as having branch, central, or hemi-retinal vein occlusion (BRVO,\u00a0CRVO, HRVO, respectively). Because retinal vein occlusions compromise venous return from the retinal circulation, they may trigger retinal ischemia, macular edema and\/or neovascularization. Intravitreally administered biologics targeting vascular endothelial growth factor (anti-VEGF\u00a0agents; Roche\/Genentech\u2019s Avastin, Roche\/Genentech\u2019s Lucentis, Regeneron\u2019s Eylea) and corticosteroids (Allergan\u2019s Ozurdex) are used to treat macular edema following\u00a0RVO. Although the pipeline for emerging\u00a0RVO\u00a0therapies is sparse, commercial opportunity exists for therapies with a longer dosing duration, greater efficacy, efficacy in treatment-resistant patients, and that are administered less invasively.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What diagnostic tests are used to characterize\u00a0RVO\u00a0patients, and how are different patient subtypes treated?<\/li>\n<li>What are the key areas of unmet need and opportunity in the\u00a0RVO\u00a0market?<\/li>\n<li>What are the key drivers and limiters in the\u00a0RVO\u00a0market?<\/li>\n<li>What influence does each major player hold over the\u00a0RVO\u00a0market?<\/li>\n<li>How is the\u00a0RVO\u00a0market expected to change over the next ten years?<\/li>\n<\/ul>\n<p><strong>GEOGRAPHY<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>PRIMARY RESEARCH<\/strong><\/p>\n<p>3\u00a0KOL\u00a0interviews in April 2019<\/p>\n<p><strong>KEY COMPANIES COVERED<\/strong><\/p>\n<p>Regeneron, Roche\/Genentech, Allergan, Novartis, Aerie Pharmaceuticals, Cerevast Medical, Taiwan Liposome Company, Kodiak Sciences<\/p>\n<p><strong>KEY DRUGS COVERED\u00a0<\/strong>Avastin, Eylea, Lucentis, Ozurdex, brolucizumab, AR-1105, TLC399, KSI-301<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.<\/p>\n","protected":false},"template":"","class_list":["post-390429","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ophthalmology","biopharma-therapy-areas-retinal-vein-occlusion","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390429\/revisions"}],"predecessor-version":[{"id":393554,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390429\/revisions\/393554"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}